Plus: Here’s how Epic founder and CEO Judy Faulkner will keep her medical records company private, independent and ...

Poseida Therapeutics' lead allogeneic chimeric antigen receptor T-cell candidate it is co-developing with Roche will advance to Phase Ib.

Bristol Myers Squibb wins approval for the first novel schizophrenia drug in decades; Pfizer pulls Oxbryta from the market; ...

Avidity Biosciences, Inc. surges on positive developments in AOCs for muscular disorders, strategic partnerships, and ...

A New York federal judge has dismissed a $6.4 billion lawsuit against Bristol-Myers Squibb Co., agreeing with counsel for the ...

Over the next three months, the agency could approve a rival to a fast-selling Pfizer heart drug, a much-debated lung cancer medicine and an addition to Vertex's dominant cystic fibrosis business.

For the second time in 19 months, a federal judge in New York has dismissed a lawsuit claiming that Bristol Myers Squibb slow ...

District Judge Jesse Furman ruled that the plaintiff, UMB Bank, does not have standing to bring the case against Bristol ...

Leerink Partners analyst David Risinger has maintained their neutral stance on BMY stock, giving a Hold rating on September 26. David Risinger ...

OMass Therapeutics Expands Development Team with Key Appointments in US and UK and Announces the Nomination of Clinical Candidate Against MC2. Oxford, United Kingdo ...

On Thursday, the U.S. Food and Drug Administration (FDA) approved the drug Cobenfy which targets schizophrenia in a new way.

In the year’s fourth-largest deal, Prime Medicine Inc. will collaborate with Bristol Myers Squibb Co. (BMS) in a research collaboration and license agreement totaling $3.61 billion. The two companies ...